Prednisolone and dexamethasone are systemically absorbed after topical application of ophthalmic suspensions in healthy dogs.

OBJECTIVE: To quantify plasma concentrations of prednisolone and dexamethasone (peripheral and jugular) and cortisol following topical ophthalmic application of 1% prednisolone acetate and 0.1% dexamethasone to healthy adult dogs. ANIMALS: 12 purpose-bred Beagles. PROCEDURES: Dogs received 1 drop of 1% prednisolone acetate (n = 6) or neomycin polymyxin B dexamethasone (ie, 0.1% dexamethasone; 6) ophthalmic suspension in both eyes every 6 hours for 14 days. Blood samples (peripheral and jugular) were collected on days 0, 1, 7, and 14 and analyzed for plasma prednisolone and dexamethasone concentrations. Plasma cortisol concentrations were measured at the beginning of the study and following topical drug administration. RESULTS: Both drugs demonstrated systemic absorption. Prednisolone was detected on days 1, 7, and 14 (median plasma concentration, 24.80 ng/mL; range, 6.20 to 74.00 ng/mL), and dexamethasone was detected on days 1, 7, and 14 (2.30 ng/mL; 0 to 17.70 ng/mL). Neither prednisolone nor dexamethasone were detected in plasma samples on day 0 (baseline). Sampling from the jugular vein resulted in higher plasma drug concentrations than from a peripheral vein when samples from each day were combined. Plasma cortisol concentrations were significantly lower than baseline following 14 days of treatment with topical prednisolone acetate and dexamethasone. CLINICAL RELEVANCE: Prednisolone and dexamethasone are detected in the plasma of healthy dogs following topical ophthalmic administration 4 times/d with prednisolone concentrations being close to a physiologic dose of orally administered prednisolone. Additional research is needed to evaluate the systemic absorption of these medications in dogs with ocular inflammation.

Disseminated histoplasmosis with ocular adnexal involvement in seven cats.

OBJECTIVE: To describe the clinical features, diagnosis, and treatment of disseminated histoplasmosis with conjunctival and/or nictitating membrane involvement in cats. PROCEDURE: Medical records from seven cats with naturally acquired disseminated histoplasmosis and conjunctival and/or nictitating membrane lesions were reviewed for signalment, clinical findings, diagnostic results, treatment, and outcome. RESULTS: Breeds included domestic shorthair (n = 5), Maine Coon (n = 1), and Siamese mix (n = 1) with four spayed females and three castrated males. Conjunctival abnormalities were identified in four cats, and nictitating membrane lesions were identified in four cats; one cat had both a conjunctival and nictitating membrane lesion. Cytologic evaluation of lesions identified Histoplasma capsulatum organisms in two of four cases sampled, and histopathologic evaluation identified H capsulatum in both cases in which a sample was submitted. Histoplasmosis antigen testing was positive in three of four submitted samples. Initial treatment for all cats included fluconazole (median dose: 26 mg/kg/d). Median duration of follow-up was 11 months (range: 1-108 months; n = 4). Resolution of ocular adnexal lesions was achieved in three cats. Two cats had relapse of disease, one of which was subsequently euthanized. One cat with concurrent feline immunodeficiency virus (FIV) infection died one month after diagnosis of histoplasmosis. CONCLUSIONS: Histoplasmosis should be a differential diagnosis for ocular adnexal inflammatory lesions in cats.